menu
The cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030
The cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030
The cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030

The cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030

Manufacturing celltherapies is technically and financially demanding; as a result, despitetherapy developers gradually strengthening their in-house expertise, they arealso becoming increasingly reliant on contract service providers

 

Roots Analysis is pleased toannounce the publication of its recent study, titled, “Cell Therapy Manufacturing Market (3rd Edition),2019 - 2030

 

The report features an extensive study of thecurrent market landscape and future opportunities associated with cell therapymanufacturing. It focuses on both contract manufacturers, as well as developerswith in-house manufacturing facilities, offering in-depth analyses of thevarious business entities that are engaged in this domain, across differentglobal regions. Amongst other elements, the report includes:

§ An analysis of thevarious expansion initiatives undertaken by service providers, in order toaugment their respective cell therapy manufacturing capabilities, over theperiod 2015-2019.

§ An analysis of therecent partnerships focused on the manufacturing of cell-based therapies, whichhave been established in the period 2014-2019.

§ Informed estimates ofthe annual commercial and clinical demand for cell therapies, in terms ofnumber of cells produced and area dedicated to manufacturing.

§ An estimate of theoverall, installed capacity for manufacturing cell-based therapies based oninformation reported by industry stakeholders in the public domain A competitivenessanalysis of biological targets, featuring insightful pictorial summaries andrepresentations.

§ A detailed analysisof the various factors that are likely to influence the pricing of cell-basedtherapies, featuring different models / approaches that may be adopted bymanufacturers while deciding the prices of their proprietary offerings.

§  A qualitative analysis, highlighting the various factorsthat need to be taken into consideration by cell therapy developers whiledeciding whether to manufacture their respective products in-house or engagethe services of a CMO.

§ An elaboratediscussion on the role of automation technologies in improving currentmanufacturing methods.

§  A discussion on cell therapy manufacturing regulationsacross various geographies, including North America, Europe, and Asia Pacific.

§  Elaborate profiles ofkey players (industry and non-industry) that offer contract manufacturingservices.

§  A discussion onaffiliated trends, key drivers and challenges, which are likely to impact theindustry’s evolution, under a comprehensive SWOT framework.

§  A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)

§ Type of therapy

§ T-cell therapies(CAR-T therapies, TCR therapies, TIL therapies)

§ Dendritic celltherapies

§ Tumor cell therapies

§ NK cell therapies

§ Stem cell therapies

 

§ Source of cells

§ Autologous

§ Allogeneic

 

§ Scale of operation

§ Clinical

§ Commercial

 

§ Purpose ofmanufacturing

§ Contractmanufacturing

§ In-housemanufacturing

 

§ Key geographicalregions

§  North America

§  Europe

§  Asia Pacific

§  Rest of the world

 

Keycompanies covered in the report

§ BioNTech InnovativeManufacturing Services

§ Cell Therapies

§ Cell and Gene TherapyCatapult

§ Center for Cell andGene Therapy, Baylor College of Medicine

§ Centre for CellManufacturing Ireland, National University of Ireland

§ Clinical Cell andVaccine Production Facility, University of Pennsylvania

§ Cognate BioServices

§ FUJIFILM

§ Guy’s and St. Thomas’GMP Facility, Guy’s Hospital

§ Hitachi Chemical

§ KBI Biopharma

§ Laboratory for Celland Gene Medicine, Stanford University

§ Lonza

§ MaSTherCell

§ MEDINET

§ Molecular andCellular Therapeutics, University of Minnesota

§ Newcastle CellularTherapies Facility, Newcastle University

§ Nikon CeLL innovation

§ Rayne Cell TherapySuite, King’s College London

§ Roslin Cell Therapies

§ Scottish NationalBlood Transfusion Services Cellular Therapy Facility, Scottish Centre forRegenerative Medicine

§ Sydney Cell and GeneTherapy

§ WuXi AdvancedTherapies

 

Foradditional details, please visit - https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.htmlor email sales@rootsanalysis.com

 

Youmay also be interested in the following titles:

1.    Celland Advanced Therapies Supply ChainManagement Market, 2019-2030

2.    RNAiTherapeutics Market (2nd Edition), 2019 –2030

3.    GeneTherapy Market (3rd Edition), 2019 – 2030

4.    StemCell Therapy Contract ManufacturingMarket, 2019-2030

 

Contact:

GauravChaudhary

+1(415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com